27 January 2023

ATAD III Directive Proposal legislative process: Vote of the EU Parliament Report

On 17 January 2023, the European Parliament has adopted its final Report on the so-called ATAD III Directive Proposal on the misuse of shell entities for tax purposes drafted by the European Commission.

Although this Report has no binding effect on the Council, it contains indications as to the directions in which the final Directive may be heading. In this respect, the report highlights the need for legal clarification, the guarantee of a balance in the market and the improvement of enforcement.

This report is thus particularly valuable for companies potentially covered, which will be soon required to self-assess their substance status under ATAD III.

This GSK Update provides an overview of the Directive Proposal, the core elements of the Report, as well as its prospective relevance for the ongoing legislative process.

Print


Press contact
Beate Dünschede
+352 271802-29
beate.duenschede@gsk-lux.com

Back

GSK Updates
  • 28.02.2024

    GSK Update: GSK Stockmann contributed to the publication of the International Comparative Legal Guide to Mergers and Acquisitions

    Read more
  • 12.02.2024

    GSK Update: ESG regulation – an outlook on developments for the year 2024

    Read more
  • 12.02.2024

    GSK Update: Green securitisations under the new Europe-an Green Bonds Regulation

    Read more
Contact person

Mathilde Ostertag

Partner

+352 271802-60

mathilde.ostertag@gsk-lux.com

Katharina Schiffmann

Counsel

+352 271802-61

katharina.schiffmann@gsk-lux.com

Elise Boscher

Associate

+352 271802-620

elise.boscher@gsk-lux.com

© GSK Stockmann 2024